intro arti symposium

1
Introduction artemisinin symposium Silvio
Gabriel, Executive Vice President and Head of
Malaria Initiatives
2
Introduction artemisinin symposium

• Silvio Gabriel, Executive Vice President and Head
  of Malaria Initiatives
• York, October 9, 2008

3
Challenge of unprecedented scale-up
Production meets demand but still frequent
stock outs at health facility levels
In millions of treatments
Deliveries
Excess production capacity
Produced, but not picked up in 2005
Max. capacity 100 mio Tx p.a.
34
38
7
66
62
ErraticOrders
33
Funding Uncertain
Supply Challenges
Global Policy Uncertain
4
9
1.3
0.1
0.2
14 mio Tx were ordered for delivery in 2005, but
only 9 mio were picked up
4
Critical Factors for switch to new API or
substitution of existing API

• Unprecedented Scale-up of Coartem
• Global Policy Uncertain
• Uncertain funding
• Supply challenges
• Erratic orders
• Production meets demand but still frequent
  stock outs at health facility levels

• Switch to new API or substitute existing API
• Clinical evidence (Bio-equivalence Clinical
  Trials)
• Regulatory approval
• Compete with current suppliers to generate demand
  from ACT producers
• Timely availability

5
Scale-up challenges for new artemisinin
Deliveries of new API
Timely Availability
Uncertain demand
Compete with current API suppliers
Regulatory Approval
Clinical Evidence
14 mio Tx were ordered for delivery in 2005, but
only 9 mio were picked up